The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis [Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi]

Basit Öğe Kaydı
dc.contributor.authorTikiz H.
dc.contributor.authorArslan Ö.
dc.contributor.authorPirildar T.
dc.contributor.authorTikiz C.
dc.contributor.authorBayindir P.
dc.date.accessioned2019-10-26T22:38:46Z
dc.date.available2019-10-26T22:38:46Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: To investigate the effects of tumor necrosis factor (TNF)-< antagonism with etanercept (ENC) on endothelial functions in patients with active rheumatoid arthritis (RA). Methods: A total of 21 patients with RA were enrolled in this prospective study. Eleven of them (8 women, 3 men mean age 47.0±10.1 years) with high disease activity despite the conventional treatment were assigned to Group 1 and were given ENC treatment twice a week (25 mg SC injection) for 12 weeks. Ten patients with RA (8 women, 2 men mean age 55.0±6.4 years) under conventional methotrexate and prednisone therapy were assigned as Control group (Group 2). Endothelium-dependent and -independent vasodilator responses of the brachial artery were assessed by high-resolution ultrasound. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured at baseline and at the post treatment period. Mann-Whitney U and Wilcoxon tests were used to compare the data and correlation analysis was performed using Pearson correlation test. Results: Endothelium-dependent vasodilatation improved from 5.2±0.8% to 7.9±1.3% (p=0.04) in ENC group, while no significant change was observed in the control group (from 6.6±1.1% to 7.0±1.8% p=0.67). No significant changes were found in endothelium-independent vasodilatation and baseline brachial artery diameters in both groups. A significant reduction in ESR and CRP were observed in patients receiving ENC (from 16.2±6.8 to 9.2± 5.1 mm/h, p=0.003 and from 14.68±3.4 to 9.25± 3.7 mg/L, p=0.003, respectively). Conclusion: Treatment with ENC for 12 weeks significantly improved endothelial function in patients with active RA compared to those under conventional therapy. The findings of the present study support the hypothesis that the use of TNF-< blockers in patients with active RA may reduce the high incidence of cardiovascular complications. (Anadolu Kardiyol Derg 2010; 10: 98-103) © Copyright 2010 by AVES Yayincilik Ltd.en_US
dc.identifier.doi10.5152/akd.2010.031en_US
dc.identifier.endpage103en_US
dc.identifier.issn1302-8723
dc.identifier.issue2en_US
dc.identifier.pmid20382605en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage98en_US
dc.identifier.urihttps://doi.org/10.5152/akd.2010.031
dc.identifier.urihttps://hdl.handle.net/11454/19948
dc.identifier.volume10en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofAnadolu Kardiyoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEndothelial functionen_US
dc.subjectEtanercepten_US
dc.subjectRheumatoid arthritisen_US
dc.subjectTumor necrosis factor-alphaen_US
dc.titleThe effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis [Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu